Name: 글로벌 시장 동향
SKU: PH8592
Availability: InStock

보고서 요약(국문)

개요
전 세계 급성 신부전 시장은 2023년 530만 달러 규모에 도달했으며, 2024년부터 2031년까지 연평균 9.0%의 성장률을 보이며 2031년에는 1,102만 달러에 이를 것으로 예상됩니다.
급성 신부전(ARF), 또는 급성 신손상(AKI)은 심각한 탈수, 감염, 특정 약물, 또는 당뇨병이나 고혈압과 같은 기저 질환 등 여러 요인으로 인해 신장 기능이 갑자기 저하되는 질환입니다. 이는 신장이 노폐물과 과도한 체액을 걸러내지 못하게 하여 체내에 독성 물질이 축적되는 결과를 초래합니다. 급성 신부전은 소변량 감소, 체액 저류, 전해질 불균형, 그리고 잠재적으로 생명을 위협하는 합병증을 특징으로 합니다. 신속한 진단과 치료는 급성 신부전을 관리하고 만성 신장 질환으로의 진행을 예방하는 데 매우 중요합니다.

시장 동향: 성장 동인 및 제약 요인
신장 질환 유병률 증가
만성 질환, 고령화, 진단 능력 향상 등의 요인으로 인해 급성 신부전(ARF) 유병률이 증가하고 있으며, 이는 치료 시장에 영향을 미치고 있습니다. 이러한 추세는 효과적인 치료 옵션에 대한 수요 증가로 이어지고 있습니다.
예를 들어, NCBI에 발표된 논문에 따르면 급성 신부전은 입원 환자에게서 흔히 관찰됩니다. 미국에서는 전체 입원 환자의 1%가 입원 시 급성 신손상(AKI)을 앓고 있습니다. 입원 기간 동안 급성 신손상 발생률은 약 2~5%이며, 중환자실 입원 환자의 최대 67%에서 발생합니다. 따라서 AKI는 입원 기간 연장 및 환자 이환율 증가의 중요한 원인입니다.
약물 관련 부작용
급성 신부전 치료에는 이뇨제, 혈관수축제, 적혈구 생성 자극제(ESA), 인산 결합제, 항생제 등 다양한 약물이 사용됩니다. 이러한 약물은 탈수, 전해질 불균형, 저혈압, 부정맥, 조직 허혈, 심각한 고혈압, 혈전색전증, 위장 문제, 항생제 내성 등의 부작용을 유발할 수 있습니다.
신장 기능 장애를 악화시키거나 추가적인 건강 문제를 유발하지 않도록 이러한 부작용을 신중하게 관리하는 것이 중요합니다. 적절한 치료와 회복을 위해서는 이러한 약물을 면밀히 모니터링하는 것이 필수적입니다.
시장 세분화 분석
전 세계 급성 신부전 시장은 질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 유형 부문에서 이뇨제는 급성 신부전 시장 점유율의 약 41.1%를 차지했습니다.
이뇨제는 급성 신부전에서 체액 과부하 및 전해질 불균형을 관리하는 데 필수적입니다. 이뇨제는 소변 생성을 증가시켜 체액량을 감소시키고 폐부종 및 고혈압과 같은 합병증을 예방합니다. 이뇨제는 고칼륨혈증과 같은 전해질 불균형도 관리하는데, 이는 신장 결석과 흔히 연관됩니다. 그러나 이뇨제 사용 시에는 탈수 및 전해질 불균형과 같은 잠재적인 부작용을 피하기 위해 주의 깊게 모니터링해야 합니다. 이러한 부작용은 신장에 더욱 부담을 줄 수 있습니다.
예를 들어, 2023년 12월 밴더빌트 대학교 의료센터에서 100만 명 이상의 성인을 대상으로 실시한 새로운 유전자 연관성 연구는 티아지드계 이뇨제가 신장 결석 예방에 효과적이라는 결과를 보여주었습니다. 신장 결석은 전 세계 인구의 약 10%에게 영향을 미칩니다. 30년 이상 동안 고혈압 치료에 흔히 사용되는 티아지드계 이뇨제는 소변으로 칼슘 배설을 감소시키기 때문에 신장 결석 예방의 표준 치료법으로 사용되어 왔습니다.

시장 지역별 점유율
북미는 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
북미는 신제품 출시, FDA 승인, 급성 신부전 환자 증가 등 여러 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 전망됩니다.
예를 들어, 2023년 1월 미국 식품의약국(FDA)은 만성 신장 질환(CKD) 성인 환자의 신장 질환 진행 및 심혈관 사망 위험 감소를 위한 잠재적 치료제로 연구 중인 자디앙스(엠파글리플로진) 정제에 대한 추가 신약 허가 신청(sNDA)을 승인했습니다.

시장 세분화
질병 유형별
신전성 급성 신부전
신성 급성 신부전
신후성 급성 신부전
약물 유형별
이뇨제
혈관수축제
적혈구 생성 자극제(ESA)
인산염 결합제
칼슘 및 비타민 D 보충제
항생제
기타
투여 경로별
경구
정맥 주사
유통 채널별
병원 약국
소매 약국
온라인 약국
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
시장의 주요 글로벌 업체는 다음과 같습니다. 노바티스, 프레제니우스 메디컬 케어, 암젠, 로슈, 박스터 인터내셔널, 자이파마, 네이처 메이드, 화이자, GSK, 일라이 릴리 등이 포함됩니다.

보고서 구매 이유
질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 급성 신부전 시장 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악하기 위해
트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해
모든 세그먼트를 포함한 급성 신부전 시장 수준의 다양한 데이터 포인트가 담긴 엑셀 데이터 시트 제공
심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공
모든 주요 플레이어의 핵심 제품을 포함하는 제품 매핑 엑셀 파일 제공
글로벌 급성 신부전 시장 보고서는 약 64개의 표, 61개의 그림, 186페이지 분량으로 구성
주요 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Overview
The Global Acute Renal Failure Market reached US$ 5.30 million in 2023 and is expected to reach US$ 11.02 million by 2031, growing at a CAGR of 9.0% during the forecast period 2024-2031.
Acute renal failure (ARF), also known as acute kidney injury (AKI), is a sudden decline in kidney function caused by factors like severe dehydration, infections, certain medications, or underlying medical conditions like diabetes or hypertension. It results in the kidneys' inability to filter waste products and excess fluids, leading to the accumulation of toxic substances in the body. ARF is characterized by decreased urine output, fluid retention, electrolyte imbalances, and potentially life-threatening complications. Prompt diagnosis and treatment are crucial for managing ARF and preventing its progression to chronic kidney disease.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of kidney diseases
The increasing prevalence of acute renal failure (ARF) is influencing the treatment market, driven by factors like chronic diseases, aging populations, and improved diagnostic capabilities. This leads to a surge in demand for effective treatment options.
For instance, according to an article published in NCBI, acute renal failure is commonly seen in hospitalized patients. In the United States, 1% of all hospital admissions have AKI on admission. During hospitalization, the approximate incidence rate of acute kidney injury is 2% to 5%, and it occurs in up to 67% of patients admitted to the intensive care unit. AKI is thus an important contributor to more extended hospital stays and patient morbidity.
Side effects associated with the drugs
Acute renal failure treatment often involves various drugs, including diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, antibiotics, and antibiotics. These drugs can cause side effects like dehydration, electrolyte imbalances, hypotension, arrhythmias, tissue ischemia, severe hypertension, thromboembolic events, hypertension, gastrointestinal issues, and antibiotic resistance.
It is crucial to manage these side effects carefully to avoid exacerbating renal dysfunction or causing additional health problems. It is essential to monitor these medications closely to ensure proper treatment and recovery.
Market Segment Analysis
The global acute renal failure market is segmented based on disease type, drug type, route of administration, distribution channel, and region.
The diuretics from the drug type segment accounted for approximately 41.1% of the acute renal failure market share
The diuretics from the drug type segment accounted for approximately 41.1%. Diuretics are essential in acute renal failure to manage fluid overload and electrolyte imbalances. They increase urine production, reducing fluid volume and preventing complications like pulmonary edema and hypertension. They also manage electrolyte disturbances like hyperkalemia, often associated with the condition. However, the use of diuretics must be monitored to avoid potential side effects like dehydration and electrolyte imbalances, which can further stress the renal system.
For instance, in December 2023, A new Vanderbilt University Medical Center genetic association study of more than 1 million adults supported the use of thiazide diuretics for kidney stone prevention. Kidney stones affect nearly 10% of the global population. For more than three decades, thiazide diuretics, a common medication used for high blood pressure, have been the standard of care for kidney stone prevention because they reduce the excretion of urinary calcium.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, FDA approvals, a rise in cases of acute renal failure, and other factors that help the region to grow during the forecast period.
For instance, in January 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).
Market Segmentation
By Disease Type
Prerenal Acute Renal Failure
Renal Acute Renal Failure
Postrenal Acute Renal Failure
By Drug Type
Diuretics
Vasopressors
Erythropoiesis-Stimulating Agents (ESAs)
Phosphate Binders
Calcium and Vitamin D Supplements
Antibiotics
Others
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Novartis, Fresenius Medical Care, Amgen, Roche, Baxter International Inc, Zypharma, Nature Made, Pfizer, GSK, and Eli Lilly among others.
Why Purchase the Report?
To visualize the global acute renal failure market segmentation based on disease type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the acute renal failure market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global acute renal failure market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of kidney diseases
4.1.1.2. Advancements in treatment options
4.1.2. Restraints
4.1.2.1. Side effects associated with the drugs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Prerenal Acute Renal Failure*
6.2.1. Introduction
6.3. Renal Acute Renal Failure
6.4. Postrenal Acute Renal Failure
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Diuretics*
7.2.1. Introduction
7.3. Vasopressors
7.4. Erythropoiesis-Stimulating Agents (ESAs)
7.5. Phosphate Binders
7.6. Calcium and Vitamin D Supplements
7.7. Antibiotics
7.8. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2. Market Attractiveness Index, By Route of Administration
8.3. Oral*
8.3.1. Introduction
8.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.4. Intravenous
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Fresenius Medical Care
12.3. Amgen
12.4. Roche
12.5. Baxter International Inc
12.6. Zypharma
12.7. Nature Made
12.8. Pfizer
12.9. GSK
12.10. Eli Lilly (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Novartis, 4.	Key Developments, Fresenius Medical Care, Amgen, Roche, Baxter International Inc, Zypharma, Nature Made, Pfizer, GSK

표 목록 (Tables)

List of Tables

Table 1 Global Acute Renal Failure Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Acute Renal Failure Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Acute Renal Failure Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Acute Renal Failure Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Acute Renal Failure Market Value, By Country, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Acute Renal Failure Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Acute Renal Failure Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 8 Global Acute Renal Failure Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Acute Renal Failure Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 10 Global Acute Renal Failure Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Acute Renal Failure Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Acute Renal Failure Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Acute Renal Failure Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Acute Renal Failure Market Value, By Country, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Acute Renal Failure Market Value, By Country, 2022-2031 (US$ Million)

Table 16 North America Acute Renal Failure Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 17 North America Acute Renal Failure Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 18 North America Acute Renal Failure Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Acute Renal Failure Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Acute Renal Failure Market Value, By 0, 2022-2031 (US$ Million)

Table 21 South America Acute Renal Failure Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 South America Acute Renal Failure Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 23 South America Acute Renal Failure Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 South America Acute Renal Failure Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 South America Acute Renal Failure Market Value, By 0, 2022-2031 (US$ Million)

Table 26 Europe Acute Renal Failure Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 27 Europe Acute Renal Failure Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 28 Europe Acute Renal Failure Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Acute Renal Failure Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Acute Renal Failure Market Value, By 0, 2022-2031 (US$ Million)

Table 31 Asia Pacific Acute Renal Failure Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 32 Asia Pacific Acute Renal Failure Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 33 Asia Pacific Acute Renal Failure Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 Asia Pacific Acute Renal Failure Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 Asia Pacific Acute Renal Failure Market Value, By 0, 2022-2031 (US$ Million)

Table 36 Middle East and Africa Acute Renal Failure Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 37 Middle East and Africa Acute Renal Failure Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 38 Middle East and Africa Acute Renal Failure Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East and Africa Acute Renal Failure Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Middle East and Africa Acute Renal Failure Market Value, By 0, 2022-2031 (US$ Million)

Table 41 Novartis: Overview

Table 42 Novartis: Product Portfolio

Table 43 Novartis: Key Developments

Table 44 Fresenius Medical Care: Overview

Table 45 Fresenius Medical Care: Product Portfolio

Table 46 Fresenius Medical Care: Key Developments

Table 47 Amgen: Overview

Table 48 Amgen: Product Portfolio

Table 49 Amgen: Key Developments

Table 50 Roche: Overview

Table 51 Roche: Product Portfolio

Table 52 Roche: Key Developments

Table 53 Baxter International Inc: Overview

Table 54 Baxter International Inc: Product Portfolio

Table 55 Baxter International Inc: Key Developments

Table 56 Zypharma: Overview

Table 57 Zypharma: Product Portfolio

Table 58 Zypharma: Key Developments

Table 59 Nature Made: Overview

Table 60 Nature Made: Product Portfolio

Table 61 Nature Made: Key Developments

Table 62 Pfizer: Overview

Table 63 Pfizer: Product Portfolio

Table 64 Pfizer: Key Developments

Table 65 GSK: Overview

Table 66 GSK: Product Portfolio

Table 67 GSK: Key Developments

Table 68 Eli Lilly: Overview

Table 69 Eli Lilly: Product Portfolio

Table 70 Eli Lilly: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 2 Global Acute Renal Failure Market Share, By Disease Type, 2023 & 2031 (%)

Figure 3 Global Acute Renal Failure Market Share, By Drug Type, 2023 & 2031 (%)

Figure 4 Global Acute Renal Failure Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 5 Global Acute Renal Failure Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 6 Global Acute Renal Failure Market Share, By Country, 2023 & 2031 (%)

Figure 7 Global Acute Renal Failure Market Y-o-Y Growth, By Disease Type, 2023-2031 (%)

Figure 8 Prerenal Acute Renal Failure Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 9 Renal Acute Renal Failure Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 10 Postrenal Acute Renal Failure Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 11 Global Acute Renal Failure Market Y-o-Y Growth, By Drug Type, 2023-2031 (%)

Figure 12 Diuretics Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 13 Vasopressors Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 14 Erythropoiesis-Stimulating Agents (ESAs) Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 15 Phosphate Binders Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 16 Calcium and Vitamin D Supplements Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 17 Antibiotics Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 18 Others Drug Type in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 19 Global Acute Renal Failure Market Y-o-Y Growth, By Route of Administration, 2023-2031 (%)

Figure 20 Oral Route of Administration in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 21 Intravenous Route of Administration in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 22 Global Acute Renal Failure Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 23 Hospital Pharmacies Distribution Channel in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 24 Retail Pharmacies Distribution Channel in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 25 Online Pharmacies Distribution Channel in Global Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 26 Global Acute Renal Failure Market Y-o-Y Growth, By Country, 2023-2031 (%)

Figure 27 North America Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 28 North America Acute Renal Failure Market Share, By Disease Type, 2023 & 2031 (%)

Figure 29 North America Acute Renal Failure Market Share, By Drug Type, 2023 & 2031 (%)

Figure 30 North America Acute Renal Failure Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 31 North America Acute Renal Failure Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 32 North America Acute Renal Failure Market Share, By 0, 2023 & 2031 (%)

Figure 33 South America Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 34 South America Acute Renal Failure Market Share, By Disease Type, 2023 & 2031 (%)

Figure 35 South America Acute Renal Failure Market Share, By Drug Type, 2023 & 2031 (%)

Figure 36 South America Acute Renal Failure Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 37 South America Acute Renal Failure Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 38 South America Acute Renal Failure Market Share, By 0, 2023 & 2031 (%)

Figure 39 Europe Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 40 Europe Acute Renal Failure Market Share, By Disease Type, 2023 & 2031 (%)

Figure 41 Europe Acute Renal Failure Market Share, By Drug Type, 2023 & 2031 (%)

Figure 42 Europe Acute Renal Failure Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 43 Europe Acute Renal Failure Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 44 Europe Acute Renal Failure Market Share, By 0, 2023 & 2031 (%)

Figure 45 Asia Pacific Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 46 Asia Pacific Acute Renal Failure Market Share, By Disease Type, 2023 & 2031 (%)

Figure 47 Asia Pacific Acute Renal Failure Market Share, By Drug Type, 2023 & 2031 (%)

Figure 48 Asia Pacific Acute Renal Failure Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 49 Asia Pacific Acute Renal Failure Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 50 Asia Pacific Acute Renal Failure Market Share, By 0, 2023 & 2031 (%)

Figure 51 Middle East and Africa Acute Renal Failure Market Value, 2022-2031 (US$ Million)

Figure 52 Middle East and Africa Acute Renal Failure Market Share, By Disease Type, 2023 & 2031 (%)

Figure 53 Middle East and Africa Acute Renal Failure Market Share, By Drug Type, 2023 & 2031 (%)

Figure 54 Middle East and Africa Acute Renal Failure Market Share, By Route of Administration, 2023 & 2031 (%)

Figure 55 Middle East and Africa Acute Renal Failure Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 56 Novartis: Financials

Figure 57 Fresenius Medical Care: Financials

Figure 58 Amgen: Financials

Figure 59 Roche: Financials

Figure 60 Baxter International Inc: Financials

Figure 61 Zypharma: Financials

Figure 62 Nature Made: Financials

Figure 63 Pfizer: Financials

Figure 64 GSK: Financials

Figure 65 Eli Lilly: Financials

세계 급성 신부전 시장 – 2024-2031

Global Acute Renal Failure Market - 2024-2031